Medicamentos anticrisis de elección para crisis focales y generalizadas en adultos.

Saved in:
Bibliographic Details
Title: Medicamentos anticrisis de elección para crisis focales y generalizadas en adultos.
Alternate Title: First-choice anti-seizure medications for focal and generalized seizures in adults.
Authors: Martínez-Piña, Daniel A.1, Vázquez-Hernández, Oscar I.2, Martínez-Juárez, Iris E.2 imartinez@innn.edu.mx
Source: Revista Mexicana de Neurociencia. 2026 Supplement, Vol. 27, p67-78. 12p.
Abstract (English): Antiseizure medications (ASM) remain the cornerstone of epilepsy treatment. Selection should be individualized based on seizure type, mechanism of action, pharmacokinetics, dose, comorbidities, and availability in Mexico. Monotherapy achieves seizure control in 50 to 70% of cases; in the remaining cases, a second ASM or additional strategies are required. This guideline updates recommendations for focal and generalized seizures in adults, based on evidence from 2022 through 2025. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): Los medicamentos anticrisis (MAC) son el pilar del tratamiento de la epilepsia. La elección debe individualizarse considerando tipo de crisis epilépticas, mecanismo de acción, farmacocinética, dosis, comorbilidades y disponibilidad en México. La monoterapia logra control de crisis en el 50 a 70% de los casos; el resto requerirá un segundo MAC o estrategias adicionales en situaciones especiales. Esta guía actualiza las recomendaciones para crisis focales y generalizadas en adultos, basada en evidencia del 2022 al 2025. [ABSTRACT FROM AUTHOR]
Copyright of Revista Mexicana de Neurociencia is the property of Academia Mexicana de Neurologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 195358914
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Medicamentos anticrisis de elección para crisis focales y generalizadas en adultos.
– Name: TitleAlt
  Label: Alternate Title
  Group: TiAlt
  Data: First-choice anti-seizure medications for focal and generalized seizures in adults.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Martínez-Piña%2C+Daniel+A%2E%22">Martínez-Piña, Daniel A.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Vázquez-Hernández%2C+Oscar+I%2E%22">Vázquez-Hernández, Oscar I.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Martínez-Juárez%2C+Iris+E%2E%22">Martínez-Juárez, Iris E.</searchLink><relatesTo>2</relatesTo><i> imartinez@innn.edu.mx</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Revista+Mexicana+de+Neurociencia%22">Revista Mexicana de Neurociencia</searchLink>. 2026 Supplement, Vol. 27, p67-78. 12p.
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: Antiseizure medications (ASM) remain the cornerstone of epilepsy treatment. Selection should be individualized based on seizure type, mechanism of action, pharmacokinetics, dose, comorbidities, and availability in Mexico. Monotherapy achieves seizure control in 50 to 70% of cases; in the remaining cases, a second ASM or additional strategies are required. This guideline updates recommendations for focal and generalized seizures in adults, based on evidence from 2022 through 2025. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: Los medicamentos anticrisis (MAC) son el pilar del tratamiento de la epilepsia. La elección debe individualizarse considerando tipo de crisis epilépticas, mecanismo de acción, farmacocinética, dosis, comorbilidades y disponibilidad en México. La monoterapia logra control de crisis en el 50 a 70% de los casos; el resto requerirá un segundo MAC o estrategias adicionales en situaciones especiales. Esta guía actualiza las recomendaciones para crisis focales y generalizadas en adultos, basada en evidencia del 2022 al 2025. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Revista Mexicana de Neurociencia is the property of Academia Mexicana de Neurologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=195358914
RecordInfo BibRecord:
  BibEntity:
    Languages:
      – Code: spa
        Text: Spanish
    PhysicalDescription:
      Pagination:
        PageCount: 12
        StartPage: 67
    Titles:
      – TitleFull: Medicamentos anticrisis de elección para crisis focales y generalizadas en adultos.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Martínez-Piña, Daniel A.
      – PersonEntity:
          Name:
            NameFull: Vázquez-Hernández, Oscar I.
      – PersonEntity:
          Name:
            NameFull: Martínez-Juárez, Iris E.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 05
              Text: 2026 Supplement
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 16655044
          Numbering:
            – Type: volume
              Value: 27
          Titles:
            – TitleFull: Revista Mexicana de Neurociencia
              Type: main
ResultId 1